VKH
ACOR

Virtu KCG Holdings’s Acorda Therapeutics ACOR Stock Holding History

Virtu KCG Holdings’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-216
Closed -$544K – 3637
2017
Q1 		$544K Buy
216
+96
+80% +$276K 0.02% 1294
2016
Q4 		$272K Buy
+120
New +$285K 0.01% 2218
2016
Q2 		– Sell
-122
Closed -$387K – 3433
2016
Q1 		$387K Buy
122
+82
+205% +$340K 0.01% 1455
2015
Q4 		$206K Sell
40
-79
-66% -$345K ﹤0.01% 2677
2015
Q3 		$379K Buy
+119
New +$462K 0.01% 1821
2015
Q2 		– Sell
-94
Closed -$375K – 3880
2015
Q1 		$375K Buy
+94
New +$431K 0.01% 1664
2014
Q1 		– Sell
-84
Closed -$293K – 4217
2013
Q4 		$293K Buy
84
+27
+47% +$105K ﹤0.01% 2627
2013
Q3 		$235K Buy
+57
New +$246K ﹤0.01% 2929

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Virtu KCG Holdings's ACOR Position: Q2 2017 in Review

Virtu KCG Holdings sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 216 shares — an estimated $544K sold.

Virtu KCG Holdings first reported a position in ACOR in Q3 2013 and held it in 8 quarters. The position peaked at $544K in Q1 2017. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Virtu KCG Holdings reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 216 Acorda Therapeutics shares in Q2 2017, an estimated $544K.
  • Virtu KCG Holdings first reported a position in Acorda Therapeutics in Q3 2013 and held it in 8 quarters.
  • Virtu KCG Holdings's Acorda Therapeutics position peaked at $544K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.